Related Experiment Video
Updated: Aug 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Drugs for cardiovascular disease. Spoilt for choice?
1University of Leicester, Faculty of Medicine, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK.
Abstract:
It is believed that the number of drugs, and indeed different classes of drugs, potentially available for treating cardiovascular disease has increased enormously. The object of this conference, held at the Royal College of Physicians in London on 1st and 2nd May 1997, was to evaluate both current treatment options and alternative research strategies.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management

